PUBLISHER: TechSci Research | PRODUCT CODE: 1807147
PUBLISHER: TechSci Research | PRODUCT CODE: 1807147
Peripheral Blood Mononuclear Cells Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product, By Application, By Techniques, By Source, By Region and Competition, 2020-2030F
We offer 8 hour analyst time for an additional research. Please contact us for the details.
Global Peripheral Blood Mononuclear Cells Market was valued at USD 280.89 million in 2024 and is expected to reach USD 496.02 million by 2030 with a CAGR of 10.02% during the forecast period. The global market for Peripheral Blood Mononuclear Cells is experiencing significant growth, driven by the rising rate in number of cell therapies, high demand of research and development for toxicology testing and reaction mechanism of the compound responsible for new and stable development of products. For instance, in June 2023, a study published in National Library of Medicine, it assessed the immune response of peripheral blood mononuclear cells (PBMC) that were infected in vitro with the Colombian strain (Col) of Trypanosoma cruzi and treated with Benzonidazole.
| Market Overview | |
|---|---|
| Forecast Period | 2026-2030 |
| Market Size 2024 | USD 280.89 Million |
| Market Size 2030 | USD 496.02 Million |
| CAGR 2025-2030 | 10.02% |
| Fastest Growing Segment | Immunology |
| Largest Market | North America |
Key Market Drivers
Government-Funded Cell Therapy and Immunology Research
Governments worldwide are significantly increasing investments in cell and gene therapy, where PBMCs play a critical role. In the U.S., the National Institutes of Health (NIH) continues to back programs-such as immuno-oncology and vaccine research-that rely heavily on PBMC-based assays to characterize immune responses before and after experimental treatments. NIH-funded vaccine programs studying T-cell immunity routinely isolate PBMCs from donors to quantify immunogenicity in clinical testing. Similarly, in Europe, the Innovative Medicines Initiative (IMI)-a €2 billion public-private partnership co-funded by the European Commission-supports drug development platforms that use PBMC-based biomarker identification and immune monitoring in early-phase clinical trials. This large-scale public-sector support for PBMC-integrated therapeutics research underlines PBMCs' indispensable role in translational medicine and offers a robust, policy-backed driver for market expansion.
Key Market Challenges
Regulatory and Quality Compliance Complexity
A significant challenge arises from the stringent and fragmented regulatory frameworks governing PBMC collection, processing, and distribution across jurisdictions. In the European Union, PBMC isolation facilities must conform to EU Tissue and Cells Directives (EUTCD) as well as national regulatory agency audits (e.g., Germany's Paul-Ehrlich-Institut), with repeat compliance checks and data privacy enforcement under GDPR-violations can incur fines exceeding €20 million. In China, PBMC processing kits are treated as Class III medical devices requiring clinical validation, and export of PBMC samples with human genetic information is restricted under the 2021 Biosecurity Law, mandating dual approvals from NMPA and the Ministry of Commerce. These variable, complex regulations raise costs for cross-border research and discourage adoption in regions without harmonized oversight, inhibiting global standardization and scalable PBMC usage.
Key Market Trends
Expanding Role in Vaccine Development and Immuno-Monitoring
A rapidly emerging trend is the expanded application of PBMCs for vaccine research and immunogenicity evaluation, especially in government-backed vaccine rollouts and pandemic preparedness. PBMCs offer critical insight into T-cell responses, cytokine profiles, and durability of immune memory. Governments funding large-scale vaccine trials-for diseases like COVID-19, malaria, tuberculosis-routinely incorporate PBMC-based assays into protocols to evaluate safety and immune efficacy. This creates predictable public-sector demand for standardized PBMC isolation, storage, and testing services, accelerating market growth tied to national immunization programs.
Key Market Players
- Charles River Laboratories International, Inc.
- Lonza Group AG
- Corning Inc.
- Bio-Rad Laboratories Inc.
- ABCAM
- Biolegend Inc.
- ZEN-Bio Inc.
- DAPCEL, Inc.
- Creative Bioarray
- iXCells Biotechnologies USA, LLC
Report Scope:
In this report, the Global Peripheral Blood Mononuclear Cells Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Peripheral Blood Mononuclear Cells Market, By Product:
- Cryopreserved or Frozen PBMC
- Cultured or Fresh PBMC
- Peripheral Blood Mononuclear Cell Isolation & Viability Kits
Peripheral Blood Mononuclear Cells Market, By Application:
- Immunology
- Infectious Disease
- Hematology
- Others
Peripheral Blood Mononuclear Cells Market, By Technique:
- Density Gradient Centrifugation Process
- Leukapheresis
Peripheral Blood Mononuclear Cells Market, By Source:
- Human
- Animals
Peripheral Blood Mononuclear Cells Market, By Region:
- North America
- United States
- Mexico
- Canada
- Europe
- France
- Germany
- United Kingdom
- Italy
- Spain
- Asia-Pacific
- China
- India
- South Korea
- Japan
- Australia
- South America
- Brazil
- Argentina
- Colombia
- Middle East and Africa
- South Africa
- Saudi Arabia
- UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies presents in the Global Peripheral Blood Mononuclear Cells Market.
Available Customizations:
Global Peripheral Blood Mononuclear Cells Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to five).
Table of Contents
1. Product Overview
- 1.1. Market Definition
- 1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations
2. Research Methodology
- 2.1. Objective of the Study
- 2.2. Baseline Methodology
- 2.3. Key Industry Partners
- 2.4. Major Association and Secondary Sources
- 2.5. Forecasting Methodology
- 2.6. Data Triangulation & Validation
- 2.7. Assumptions and Limitations
3. Executive Summary
- 3.1. Overview of the Market
- 3.2. Overview of Key Market Segmentations
- 3.3. Overview of Key Market Players
- 3.4. Overview of Key Regions/Countries
- 3.5. Overview of Market Drivers, Challenges, and Trends
4. Impact of COVID-19 on Global Peripheral Blood Mononuclear Cells Market
5. Voice of Customer
6. Global Peripheral Blood Mononuclear Cells Market Outlook
- 6.1. Market Size & Forecast
- 6.1.1. By Value
- 6.2. Market Share & Forecast
- 6.2.1. By Product (Cryopreserved or Frozen PBMC, Cultured or Fresh PBMC and Peripheral Blood Mononuclear Cell Isolation & Viability Kits)
- 6.2.2. By Application (Immunology, Infectious Disease, Hematology and Others)
- 6.2.3. By Technique (Density Gradient Centrifugation Process and Leukapheresis)
- 6.2.4. By Source (Human and Animals)
- 6.2.5. By Region (North America, Europe, Asia Pacific, South America, Middle East & Africa)
- 6.2.6. By Company (2024)
- 6.3. Market Map
- 6.3.1. By Product
- 6.3.2. By Application
- 6.3.3. By Technique
- 6.3.4. By Source
- 6.3.5. By Region
7. North America Peripheral Blood Mononuclear Cells Market Outlook
- 7.1. Market Size & Forecast
- 7.1.1. By Value
- 7.2. Market Share & Forecast
- 7.2.1. By Product
- 7.2.2. By Application
- 7.2.3. By Technique
- 7.2.4. By Source
- 7.2.5. By Country
- 7.3. North America: Country Analysis
- 7.3.1. United States Peripheral Blood Mononuclear Cells Market Outlook
- 7.3.1.1. Market Size & Forecast
- 7.3.1.1.1. By Value
- 7.3.1.2. Market Share & Forecast
- 7.3.1.2.1. By Product
- 7.3.1.2.2. By Application
- 7.3.1.2.3. By Technique
- 7.3.1.2.4. By Source
- 7.3.1.1. Market Size & Forecast
- 7.3.2. Canada Peripheral Blood Mononuclear Cells Market Outlook
- 7.3.2.1. Market Size & Forecast
- 7.3.2.1.1. By Value
- 7.3.2.2. Market Share & Forecast
- 7.3.2.2.1. By Product
- 7.3.2.2.2. By Application
- 7.3.2.2.3. By Technique
- 7.3.2.2.4. By Source
- 7.3.2.1. Market Size & Forecast
- 7.3.3. Mexico Peripheral Blood Mononuclear Cells Market Outlook
- 7.3.3.1. Market Size & Forecast
- 7.3.3.1.1. By Value
- 7.3.3.2. Market Share & Forecast
- 7.3.3.2.1. By Product
- 7.3.3.2.2. By Application
- 7.3.3.2.3. By Technique
- 7.3.3.2.4. By Source
- 7.3.3.1. Market Size & Forecast
- 7.3.1. United States Peripheral Blood Mononuclear Cells Market Outlook
8. Europe Peripheral Blood Mononuclear Cells Market Outlook
- 8.1. Market Size & Forecast
- 8.1.1. By Value
- 8.2. Market Share & Forecast
- 8.2.1. By Product
- 8.2.2. By Application
- 8.2.3. By Technique
- 8.2.4. By Source
- 8.2.5. By Country
- 8.3. Europe: Country Analysis
- 8.3.1. Germany Peripheral Blood Mononuclear Cells Market Outlook
- 8.3.1.1. Market Size & Forecast
- 8.3.1.1.1. By Value
- 8.3.1.2. Market Share & Forecast
- 8.3.1.2.1. By Product
- 8.3.1.2.2. By Application
- 8.3.1.2.3. By Technique
- 8.3.1.2.4. By Source
- 8.3.1.1. Market Size & Forecast
- 8.3.2. France Peripheral Blood Mononuclear Cells Market Outlook
- 8.3.2.1. Market Size & Forecast
- 8.3.2.1.1. By Value
- 8.3.2.2. Market Share & Forecast
- 8.3.2.2.1. By Product
- 8.3.2.2.2. By Application
- 8.3.2.2.3. By Technique
- 8.3.2.2.4. By Source
- 8.3.2.1. Market Size & Forecast
- 8.3.3. United Kingdom Peripheral Blood Mononuclear Cells Market Outlook
- 8.3.3.1. Market Size & Forecast
- 8.3.3.1.1. By Value
- 8.3.3.2. Market Share & Forecast
- 8.3.3.2.1. By Product
- 8.3.3.2.2. By Application
- 8.3.3.2.3. By Technique
- 8.3.3.2.4. By Source
- 8.3.3.1. Market Size & Forecast
- 8.3.4. Italy Peripheral Blood Mononuclear Cells Market Outlook
- 8.3.4.1. Market Size & Forecast
- 8.3.4.1.1. By Value
- 8.3.4.2. Market Share & Forecast
- 8.3.4.2.1. By Product
- 8.3.4.2.2. By Application
- 8.3.4.2.3. By Technique
- 8.3.4.2.4. By Source
- 8.3.4.1. Market Size & Forecast
- 8.3.5. Spain Peripheral Blood Mononuclear Cells Market Outlook
- 8.3.5.1. Market Size & Forecast
- 8.3.5.1.1. By Value
- 8.3.5.2. Market Share & Forecast
- 8.3.5.2.1. By Product
- 8.3.5.2.2. By Application
- 8.3.5.2.3. By Technique
- 8.3.5.2.4. By Source
- 8.3.5.1. Market Size & Forecast
- 8.3.1. Germany Peripheral Blood Mononuclear Cells Market Outlook
9. Asia-Pacific Peripheral Blood Mononuclear Cells Market Outlook
- 9.1. Market Size & Forecast
- 9.1.1. By Value
- 9.2. Market Share & Forecast
- 9.2.1. By Product
- 9.2.2. By Application
- 9.2.3. By Technique
- 9.2.4. By Source
- 9.2.5. By Country
- 9.3. Asia-Pacific: Country Analysis
- 9.3.1. China Peripheral Blood Mononuclear Cells Market Outlook
- 9.3.1.1. Market Size & Forecast
- 9.3.1.1.1. By Value
- 9.3.1.2. Market Share & Forecast
- 9.3.1.2.1. By Product
- 9.3.1.2.2. By Application
- 9.3.1.2.3. By Technique
- 9.3.1.2.4. By Source
- 9.3.1.1. Market Size & Forecast
- 9.3.2. Japan Peripheral Blood Mononuclear Cells Market Outlook
- 9.3.2.1. Market Size & Forecast
- 9.3.2.1.1. By Value
- 9.3.2.2. Market Share & Forecast
- 9.3.2.2.1. By Product
- 9.3.2.2.2. By Application
- 9.3.2.2.3. By Technique
- 9.3.2.2.4. By Source
- 9.3.2.1. Market Size & Forecast
- 9.3.3. India Peripheral Blood Mononuclear Cells Market Outlook
- 9.3.3.1. Market Size & Forecast
- 9.3.3.1.1. By Value
- 9.3.3.2. Market Share & Forecast
- 9.3.3.2.1. By Product
- 9.3.3.2.2. By Application
- 9.3.3.2.3. By Technique
- 9.3.3.2.4. By Source
- 9.3.3.1. Market Size & Forecast
- 9.3.4. South Korea Peripheral Blood Mononuclear Cells Market Outlook
- 9.3.4.1. Market Size & Forecast
- 9.3.4.1.1. By Value
- 9.3.4.2. Market Share & Forecast
- 9.3.4.2.1. By Product
- 9.3.4.2.2. By Application
- 9.3.4.2.3. By Technique
- 9.3.4.2.4. By Source
- 9.3.4.1. Market Size & Forecast
- 9.3.5. Australia Peripheral Blood Mononuclear Cells Market Outlook
- 9.3.5.1. Market Size & Forecast
- 9.3.5.1.1. By Value
- 9.3.5.2. Market Share & Forecast
- 9.3.5.2.1. By Product
- 9.3.5.2.2. By Application
- 9.3.5.2.3. By Technique
- 9.3.5.2.4. By Source
- 9.3.5.1. Market Size & Forecast
- 9.3.1. China Peripheral Blood Mononuclear Cells Market Outlook
10. South America Peripheral Blood Mononuclear Cells Market Outlook
- 10.1. Market Size & Forecast
- 10.1.1. By Value
- 10.2. Market Share & Forecast
- 10.2.1. By Product
- 10.2.2. By Application
- 10.2.3. By Technique
- 10.2.4. By Source
- 10.2.5. By Country
- 10.3. South America: Country Analysis
- 10.3.1. Brazil Peripheral Blood Mononuclear Cells Market Outlook
- 10.3.1.1. Market Size & Forecast
- 10.3.1.1.1. By Value
- 10.3.1.2. Market Share & Forecast
- 10.3.1.2.1. By Product
- 10.3.1.2.2. By Application
- 10.3.1.2.3. By Technique
- 10.3.1.2.4. By Source
- 10.3.1.1. Market Size & Forecast
- 10.3.2. Argentina Peripheral Blood Mononuclear Cells Market Outlook
- 10.3.2.1. Market Size & Forecast
- 10.3.2.1.1. By Value
- 10.3.2.2. Market Share & Forecast
- 10.3.2.2.1. By Product
- 10.3.2.2.2. By Application
- 10.3.2.2.3. By Technique
- 10.3.2.2.4. By Source
- 10.3.2.1. Market Size & Forecast
- 10.3.3. Colombia Peripheral Blood Mononuclear Cells Market Outlook
- 10.3.3.1. Market Size & Forecast
- 10.3.3.1.1. By Value
- 10.3.3.2. Market Share & Forecast
- 10.3.3.2.1. By Product
- 10.3.3.2.2. By Application
- 10.3.3.2.3. By Technique
- 10.3.3.2.4. By Source
- 10.3.3.1. Market Size & Forecast
- 10.3.1. Brazil Peripheral Blood Mononuclear Cells Market Outlook
11. Middle East and Africa Peripheral Blood Mononuclear Cells Market Outlook
- 11.1. Market Size & Forecast
- 11.1.1. By Value
- 11.2. Market Share & Forecast
- 11.2.1. By Product
- 11.2.2. By Application
- 11.2.3. By Technique
- 11.2.4. By Source
- 11.2.5. By Country
- 11.3. MEA: Country Analysis
- 11.3.1. UAE Peripheral Blood Mononuclear Cells Market Outlook
- 11.3.1.1. Market Size & Forecast
- 11.3.1.1.1. By Value
- 11.3.1.2. Market Share & Forecast
- 11.3.1.2.1. By Product
- 11.3.1.2.2. By Application
- 11.3.1.2.3. By Technique
- 11.3.1.2.4. By Source
- 11.3.1.1. Market Size & Forecast
- 11.3.2. Saudi Arabia Peripheral Blood Mononuclear Cells Market Outlook
- 11.3.2.1. Market Size & Forecast
- 11.3.2.1.1. By Value
- 11.3.2.2. Market Share & Forecast
- 11.3.2.2.1. By Product
- 11.3.2.2.2. By Application
- 11.3.2.2.3. By Technique
- 11.3.2.2.4. By Source
- 11.3.2.1. Market Size & Forecast
- 11.3.3. South Africa Peripheral Blood Mononuclear Cells Market Outlook
- 11.3.3.1. Market Size & Forecast
- 11.3.3.1.1. By Value
- 11.3.3.2. Market Share & Forecast
- 11.3.3.2.1. By Product
- 11.3.3.2.2. By Application
- 11.3.3.2.3. By Technique
- 11.3.3.2.4. By Source
- 11.3.3.1. Market Size & Forecast
- 11.3.1. UAE Peripheral Blood Mononuclear Cells Market Outlook
12. Market Dynamics
- 12.1. Drivers
- 12.2. Challenges
13. Market Trends & Developments
- 13.1. Merger & Acquisition (If Any)
- 13.2. Product Launches (If Any)
- 13.3. Recent Developments
14. Porters Five Forces Analysis
- 14.1. Competition in the Industry
- 14.2. Potential of New Entrants
- 14.3. Power of Suppliers
- 14.4. Power of Customers
- 14.5. Threat of Substitute Products/Services
15. SWOT Analysis: Global Peripheral Blood Mononuclear Cells Market
16. Clinical Trial Analysis
- 16.1. Ongoing Clinical Trials
- 16.2. Completed Clinical Trials
- 16.3. Terminated Clinical Trials
- 16.4. Breakdown of Pipeline, By Development Phase
- 16.5. Breakdown of Pipeline, By Status
- 16.6. Breakdown of Pipeline, By Study Type
- 16.7. Breakdown of Pipeline, By Region
- 16.8. Clinical Trials Heat Map
17. Competitive Landscape
- 17.1. Charles River Laboratories International, Inc.
- 17.1.1. Business Overview
- 17.1.2. Company Snapshot
- 17.1.3. Products & Services
- 17.1.4. Financials (As Reported)
- 17.1.5. Recent Developments
- 17.1.6. Key Personnel Details
- 17.1.7. SWOT Analysis
- 17.2. Lonza Group AG
- 17.3. Corning Inc.
- 17.4. Bio-Rad Laboratories Inc.
- 17.5. ABCAM
- 17.6. Biolegend Inc.
- 17.7. ZEN-Bio Inc.
- 17.8. DAPCEL, Inc.
- 17.9. Creative Bioarray
- 17.10. iXCells Biotechnologies USA, LLC
18. Strategic Recommendations
19. About Us & Disclaimer
